Low-Risk Gestational Choriocarcinoma: Next Step When Methotrexate Is Not Tolerated or hCG Fails to Normalize

This protocol applies to patients with gestational choriocarcinoma classified as low risk (WHO modified prognostic index score 0–6) who have received first-line methotrexate-based therapy but cannot continue it — either due to toxicity, a contraindication, or failure to achieve the expected biochemical response.

Clinical Scenario Gestational choriocarcinoma with a WHO modified prognostic index score for gestational trophoblastic neoplasm of 0 to 6 (low risk). In this risk category, single-agent chemotherapy is the appropriate treatment intensity.

Prior Treatment & Escalation Trigger First-line therapy was single-agent methotrexate (plus leucovorin). The treatment goal of that line — normalization of serum human chorionic gonadotropin (hCG), monitored every 1 to 2 weeks — was not reached, or methotrexate was not tolerable or is contraindicated in this patient. This protocol defines the next step in that situation.

Treatment Approach (Partial) An alternative single-agent chemotherapy regimen — one that does not rely on methotrexate — is indicated in this setting. This approach has most often been used as secondary therapy when methotrexate cannot be continued. The complete regimen, full eligibility criteria, and sequencing guidance are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2023-004704

This group includes patients with a diagnosis of gestational choriocarcinoma who receive a score from 0 to 6 according to the WHO modified prognostic index score for GTN.

Consider using single-agent chemotherapy in low-risk (score <7) and multi-agent chemotherapy in high risk (score of 7 or more).

Due to its toxicity profile, 5-day actinomycin D has most often been used as secondary therapy for patients with methotrexate toxicity or contraindications to the use of methotrexate.

Actinomycin-D is often used as a second line even if it has a more toxic side effect profile (including nausea and alopecia) than methotrexate and might produce local tissue injury in case of extravasation.

View source ↗